| Dr Tariq Mahmood, MD | |
|
2828 N Glenhaven Dr, Midwest City, OK 73110-4002 | |
| (405) 732-4893 | |
| (405) 741-7820 |
| Full Name | Dr Tariq Mahmood |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 44 Years |
| Location | 2828 N Glenhaven Dr, Midwest City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992761589 | NPI | - | NPPES |
| 100021640A | Medicaid | OK | |
| 0034548 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 17627 (Oklahoma) | Secondary |
| 207RX0202X | Internal Medicine - Medical Oncology | 35C.000982 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Norman Regional | Norman, OK | Hospital |
| Alliancehealth Midwest | Midwest city, OK | Hospital |
| St Claire Regional Medical Center | Morehead, KY | Hospital |
| Entity Name | Absentee Shawnee Tribe Of Oklahoma |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942253521 PECOS PAC ID: 9335053479 Enrollment ID: O20031113000654 |
News Archive
Inova Labs, Inc. of Austin, Texas announced today the closing of the private placement of shares of its Series A Preferred Stock. The placement went to investment funds affiliated with Three Arch Partners, based in Silicon Valley, California. Inova received gross proceeds of $10.0 million from the equity financing, which will be used for nationwide and international sales expansion of its LifeChoice® portable oxygen concentrator product line, continuation of next stage developments, and working capital.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
The lining of the intestines - the epithelium - does more than absorb nutrients from your lunch. It grows, shrinks, and adjusts the very makeup of its cells in response to whatever you just ate. And understanding that process might just give scientists new insights into the behavior of cancer cells.
In a special guest editorial, Bass and colleagues discuss the limitations of current estimates of the prevalence of traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) among Operation Iraqi Freedom and Operation Enduring Freedom (OIF/OEF) veterans. Since these estimates often determine the allocation of resources, the authors urge decision makers to understand the limitations of these prevalence estimates.
Cornell University, in partnership with Memorial Sloan Kettering Cancer Center, is opening a new $10 million Center of Cancer Nanotechnology Excellence that brings together scientists, engineers, biologists and physicians to develop and translate new cancer care applications based on nanotechnology.
› Verified 5 days ago
| Entity Name | Li-si-wi-nwi Health, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124152962 PECOS PAC ID: 4183895519 Enrollment ID: O20130227000474 |
News Archive
Inova Labs, Inc. of Austin, Texas announced today the closing of the private placement of shares of its Series A Preferred Stock. The placement went to investment funds affiliated with Three Arch Partners, based in Silicon Valley, California. Inova received gross proceeds of $10.0 million from the equity financing, which will be used for nationwide and international sales expansion of its LifeChoice® portable oxygen concentrator product line, continuation of next stage developments, and working capital.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
The lining of the intestines - the epithelium - does more than absorb nutrients from your lunch. It grows, shrinks, and adjusts the very makeup of its cells in response to whatever you just ate. And understanding that process might just give scientists new insights into the behavior of cancer cells.
In a special guest editorial, Bass and colleagues discuss the limitations of current estimates of the prevalence of traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) among Operation Iraqi Freedom and Operation Enduring Freedom (OIF/OEF) veterans. Since these estimates often determine the allocation of resources, the authors urge decision makers to understand the limitations of these prevalence estimates.
Cornell University, in partnership with Memorial Sloan Kettering Cancer Center, is opening a new $10 million Center of Cancer Nanotechnology Excellence that brings together scientists, engineers, biologists and physicians to develop and translate new cancer care applications based on nanotechnology.
› Verified 5 days ago
| Entity Name | Absentee Shawnee Tribal Health Authority, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942253521 PECOS PAC ID: 5799171088 Enrollment ID: O20220414000294 |
News Archive
Inova Labs, Inc. of Austin, Texas announced today the closing of the private placement of shares of its Series A Preferred Stock. The placement went to investment funds affiliated with Three Arch Partners, based in Silicon Valley, California. Inova received gross proceeds of $10.0 million from the equity financing, which will be used for nationwide and international sales expansion of its LifeChoice® portable oxygen concentrator product line, continuation of next stage developments, and working capital.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
The lining of the intestines - the epithelium - does more than absorb nutrients from your lunch. It grows, shrinks, and adjusts the very makeup of its cells in response to whatever you just ate. And understanding that process might just give scientists new insights into the behavior of cancer cells.
In a special guest editorial, Bass and colleagues discuss the limitations of current estimates of the prevalence of traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) among Operation Iraqi Freedom and Operation Enduring Freedom (OIF/OEF) veterans. Since these estimates often determine the allocation of resources, the authors urge decision makers to understand the limitations of these prevalence estimates.
Cornell University, in partnership with Memorial Sloan Kettering Cancer Center, is opening a new $10 million Center of Cancer Nanotechnology Excellence that brings together scientists, engineers, biologists and physicians to develop and translate new cancer care applications based on nanotechnology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tariq Mahmood, MD 2828 N Glenhaven Dr, Midwest City, OK 73110-4002 Ph: (405) 732-4893 | Dr Tariq Mahmood, MD 2828 N Glenhaven Dr, Midwest City, OK 73110-4002 Ph: (405) 732-4893 |
News Archive
Inova Labs, Inc. of Austin, Texas announced today the closing of the private placement of shares of its Series A Preferred Stock. The placement went to investment funds affiliated with Three Arch Partners, based in Silicon Valley, California. Inova received gross proceeds of $10.0 million from the equity financing, which will be used for nationwide and international sales expansion of its LifeChoice® portable oxygen concentrator product line, continuation of next stage developments, and working capital.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
The lining of the intestines - the epithelium - does more than absorb nutrients from your lunch. It grows, shrinks, and adjusts the very makeup of its cells in response to whatever you just ate. And understanding that process might just give scientists new insights into the behavior of cancer cells.
In a special guest editorial, Bass and colleagues discuss the limitations of current estimates of the prevalence of traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) among Operation Iraqi Freedom and Operation Enduring Freedom (OIF/OEF) veterans. Since these estimates often determine the allocation of resources, the authors urge decision makers to understand the limitations of these prevalence estimates.
Cornell University, in partnership with Memorial Sloan Kettering Cancer Center, is opening a new $10 million Center of Cancer Nanotechnology Excellence that brings together scientists, engineers, biologists and physicians to develop and translate new cancer care applications based on nanotechnology.
› Verified 5 days ago
Dr. Stephen A Hamilton, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 230 N Midwest Blvd, Midwest City, OK 73110 Phone: 405-737-8455 Fax: 405-739-8707 | |
Dr. Mohammed Naveed Ahmed, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8121 National Ave Ste 300, Midwest City, OK 73110 Phone: 405-610-3023 Fax: 405-733-0779 | |
Dr. Bereket Alemu, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9230 E Reno Ave, Suite B, Midwest City, OK 73130 Phone: 405-737-4900 Fax: 405-737-3606 | |
Vaqar Ahmad, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8121 National Ave, Suite 402, Midwest City, OK 73110 Phone: 405-736-6095 Fax: 405-736-6682 | |
Aneesh Venkat Pakala, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 6951 Se 15th St, Midwest City, OK 73110 Phone: 405-233-0450 Fax: 405-233-0451 | |
Arif A Shakir, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 412 S Air Depot Blvd, Ste B, Midwest City, OK 73110 Phone: 405-737-2800 Fax: 405-737-2858 | |
Dr. Samson Mulu Ambaw, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9230 E. Reno Ave Suite B, Midwest City, OK 73130 Phone: 405-737-4900 Fax: 405-737-3606 |